Risk assessment and risk-based therapy in febrile neutropenic patients
- PMID: 9764547
- DOI: 10.1007/BF01691127
Risk assessment and risk-based therapy in febrile neutropenic patients
Similar articles
-
Expanding the options for risk-based therapy in febrile neutropenia.Diagn Microbiol Infect Dis. 1998 Jun;31(2):411-6. doi: 10.1016/s0732-8893(98)00034-0. Diagn Microbiol Infect Dis. 1998. PMID: 9635917 Review.
-
[Treatment of febrile neutropenia].Rinsho Ketsueki. 2009 Feb;50(2):69-72. Rinsho Ketsueki. 2009. PMID: 19265296 Review. Japanese. No abstract available.
-
Important aspects of cost-effectiveness analysis in febrile neutropenia.Infection. 1999 Nov-Dec;27(6):372-5. Infection. 1999. PMID: 10624602 No abstract available.
-
[Problems and proposals for revision of the Japanese guideline for febrile neutropenia].Rinsho Ketsueki. 2011 Apr;52(4):182-9. Rinsho Ketsueki. 2011. PMID: 21566403 Review. Japanese. No abstract available.
-
Question 2: Unexpected neutropenia in a febrile, but immunocompetent, child.Arch Dis Child. 2015 Nov;100(11):1093-5. doi: 10.1136/archdischild-2015-309497. Arch Dis Child. 2015. PMID: 26483439 Review. No abstract available.
Cited by
-
Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials.Eur J Clin Microbiol Infect Dis. 2008 Jan;27(1):53-63. doi: 10.1007/s10096-007-0397-y. Epub 2007 Oct 16. Eur J Clin Microbiol Infect Dis. 2008. PMID: 17938978
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical